ストックスクリーナーアプリを入手
23.75
1.08%
-0.26
アフターアワーズ：
23.67
-0.08
-0.34%
前日終値:
$24.01
開ける：
$24.09
24時間の取引高:
14.48M
Relative Volume:
0.42
時価総額：
$5.50B
収益：
$2.35B
当期純損益:
$128.37M
株価収益率:
45.49
EPS:
0.5221
ネットキャッシュフロー:
$57.42M
1週間 パフォーマンス:
-5.19%
1か月 パフォーマンス:
-18.13%
6か月 パフォーマンス:
-31.58%
1年 パフォーマンス:
-55.62%
1日の値動き範囲:
$23.30
$24.52
1週間の範囲:
$21.53
$24.52
52週間の値動き範囲:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
23.75 | 5.56B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | JP Morgan | Overweight |
| 2026-03-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2026-03-10 | アップグレード | Citigroup | Sell → Neutral |
| 2026-03-09 | アップグレード | Needham | Hold → Buy |
| 2026-02-24 | ダウングレード | BTIG Research | Buy → Neutral |
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers (HIMS) CMO-director gets 435 RSUs instead of $10K cash retainer - Stock Titan
Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees - Stock Titan
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees - Stock Titan
Latham Advises on Hims & Hers Health, Inc.’s Upsized US$350 Million Convertible Senior Notes Offering - Latham & Watkins LLP
HIMS Maintained by Truist Securities -- Price Target Raised to $23 - GuruFocus
Hims & Hers Deepens Personalized Care Through Platform Expansion - TradingView
Hims & Hers Has Fallen 66% From Its Peak. Does the $350M Debt Raise Signal a Turning Point or a Red Flag? - TIKR.com
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com Canada
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com Canada
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Why Hims & Hers Health Stock Just Crashed - AOL.com
Hims & Hers launches generics for Novo’s semaglutide in Canada - Seeking Alpha
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - HIMS Investor Relations
Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers - Hims & Hers Newsroom
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
Hims & Hers Health Q1 2026: Strategic Shift to Branded Medications Weighs on Results - IndexBox
Eucalyptus acquisition prospect lifts Hims & Hers Health stock 2.67% higher - Traders Union
HIMS Becomes a Retail Sentiment Standout as Bullish Mentions Rise to 70% - openPR.com
Live Longer and Better. Does Medicine’s New Obsession Really Work? - Barron's
Hims & Hers Health, Inc. - dailyvoice.com
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers stock slips as dilution fears outweigh new capital - MSN
Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital - Benzinga
Hims & Hers: Wegovy Deal Fuels Growth (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Swings to First-Quarter Loss as Weight-Loss Pivot Drives Up Costs - WSJ
Barclays Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $29 - Moomoo
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call - Yahoo Finance
Hims & Hers Health, Inc.: Shareholders Board Members Managers and Company Profile | AR0162508391 - marketscreener.com
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1 - Yahoo Finance
Hims & Hers (HIMS) CFO sells 7,950 shares after option exercise - Stock Titan
HIMS Maintained by B of A Securities -- Price Target Lowered to $28 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health Options Spot-On: On May 19th, 113.05K Contracts Were Traded, With 982.6K Open Interest - Moomoo
Why is Hims & Hers stock being hammered today? By Investing.com - Investing.com Nigeria
Is CAH Becoming the Backbone of US Healthcare Infrastructure? - TradingView
Hims & Hers Massive Stock Drop Explained - The Motley Fool
Hims & Hers Health (HIMS) Is Down 23.5% After Zero-Coupon Convertible Note OfferingWhat's Changed - simplywall.st
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering - TradingView
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):